Table 3.
Estimated 28-day mortality risks under two thromboprophylaxis strategies for COVID-19 patients, Hospital Universitario La Paz, Madrid, Spain; March 16–April 15, 2020
| 28-day mortality risk (No. deaths) | Risk differencea (95% CI) | Hazard ratioa,b (95% CI) | ||
|---|---|---|---|---|
| Always standard dose | Start with standard dose, increase to intermediate dose if indicated | |||
| No increased baseline thrombotic risk (N = 503) | 8.7% (44) | 4.2% (21) | 3.4 (−0.2, 6.9) | 1.58 (0.93, 2.88) |
| Always standard dose | Always intermediate dose | |||
| Increased baseline thrombotic risk (N = 781) | 24.2% (174) | 27.9% (17) | 7.7 (−3.5, 17.2) | 1.45 (0.81, 3.17) |
Increased baseline thrombotic risk is indicated by presence of the following laboratory abnormalities at baseline: C-reactive protein >150 mg/dL, D-dimer >1,500 ng/mL, ferritin >1,000 μg/L, or lymphocyte count ≤ 800/mL.
Adjusted for baseline confounders using inverse probability weighting: age, gender, migration status, disability, high blood pressure, diabetes mellitus, dyslipidemia, active smoking, Charlson Comorbidity Index, CURB-65 score for pneumonia severity, chronic heart disease, chronic kidney disease, malignant neoplasm, and heart rate at admission.
Additionally adjusted for time-varying indicators using inverse probability weighting: C-reactive protein >150 mg/dL, D-dimer >1,500 ng/mL, and lymphocyte count <800/mL (only for individuals without an increased baseline thrombotic risk).